Freedom Capital Markets maintains Buy rating on Astrana Health, $50 price target
I'm LongbridgeAI, I can summarize articles.Freedom Capital Markets maintained a Buy rating on Astrana Health with a $50 price target, implying 40.6% upside from the Sep 30 close of $35.57. The firm cites strong revenue growth potential, noting a 15% increase in legacy operations for Q1 2026. Despite challenges like a short-seller report and cybersecurity incident, Astrana's resilience and solid fundamentals support the positive outlook.
Freedom Capital Markets maintained their Buy rating on Astrana Health's stock with a price target of $50.00.
The price target implies an upside of 40.6% from the Sep 30 close of $35.57.
Key takeaways from the analyst note
Strong Revenue Growth Potential: Astrana Health has demonstrated a robust revenue growth trajectory, particularly in its legacy operations, which showed a 15% increase on a constant-entity basis in Q1 2026, indicating a solid foundation for future performance despite temporary setbacks from acquisitions.
Resilience Amid Challenges: The company has effectively managed to maintain its Buy rating even in the face of recent negative events, such as a short-seller report and a cybersecurity incident, suggesting strong underlying fundamentals that can withstand external pressures, providing confidence in its long-term outlook.
Explore more price target data and ratings for Astrana Health on the .